Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline.
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2013
At a glance
- Drugs Influenza virus vaccine liposomal (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- 01 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2011 Actual initiation date Oct 2011 added as reported by ClinicalTrials.gov.